SCHEMBL7055090

SCHEMBL7055090

CC[Si](CC)(OS(=O)(=O)C(F)(F)F)C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22126696 0.79 CA1 (0.30)
SCHEMBL114743 0.74
SCHEMBL2058153 0.74
SCHEMBL19665461 0.74 CA1 (0.30)
SCHEMBL631967 0.74
SCHEMBL2057215 0.74 ALDH1A1 (0.35)
SCHEMBL36993 0.74 CA1 (0.30)
SCHEMBL6686768 0.74 CA1 (0.30)
SCHEMBL8821747 0.73
SCHEMBL630910 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109206441-B Purification method of everolimus 正大天晴药业集团股份有限公司 2022-05-20 CN claimed
EP-3206695-A1 SCALABLE SYNTHESIS OF REDUCED TOXICITY DERIVATIVE OF AMPHOTERICIN B The Board of Trustees of the University of Illionis (US) 2017-08-23 EP claimed
US-20170233427-A1 SCALABLE SYNTHESIS OF REDUCED TOXICITY DERIVATIVE OF AMPHOTERICIN B THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2017-08-17 US claimed
WO-2016061437-A1 SCALABLE SYNTHESIS OF REDUCED TOXICITY DERIVATIVE OF AMPHOTERICIN B THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2016-04-21 WO claimed
CN-117558982-A Electrolyte for improving multiplying power performance and lithium ion battery 合肥国轩高科动力能源有限公司 2024-02-13 CN disclosed
CN-109206441-B Purification method of everolimus 正大天晴药业集团股份有限公司 2022-05-20 CN disclosed
EP-3929203-A1 DERIVATIVES OF AMPHOTERICIN B Sfunga Therapeutics, Inc. (US) 2021-12-29 EP disclosed
EP-3283171-B1 DERIVATIVES OF AMPHOTERICIN B SFUNGA THERAPEUTICS INC (US) 2021-05-26 EP disclosed
US-10882883-B2 Derivatives of amphotericin B SFUNGA THERAPEUTICS, INC. (US) 2021-01-05 US disclosed
US-20200262858-A1 DERIVATIVES OF AMPHOTERICIN B ELION THERAPEUTICS, INC. 2020-08-20 US disclosed
US-10683318-B2 Scalable synthesis of reduced toxicity derivative of amphotericin B THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2020-06-16 US disclosed
US-10597420-B2 Derivatives of amphotericin B SFUNGA THERAPEUTICS, INC. (US) 2020-03-24 US disclosed
EP-3206695-A1 SCALABLE SYNTHESIS OF REDUCED TOXICITY DERIVATIVE OF AMPHOTERICIN B The Board of Trustees of the University of Illionis (US) 2017-08-23 EP disclosed
US-20170233427-A1 SCALABLE SYNTHESIS OF REDUCED TOXICITY DERIVATIVE OF AMPHOTERICIN B THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2017-08-17 US disclosed
WO-2016168568-A1 DERIVATIVES OF AMPHOTERICIN B Revolution Medicines, Inc. (US) 2016-10-20 WO disclosed
US-20160304548-A1 Derivatives of Amphotericin B ELION THERAPEUTICS, INC. 2016-10-20 US disclosed
WO-2016061437-A1 SCALABLE SYNTHESIS OF REDUCED TOXICITY DERIVATIVE OF AMPHOTERICIN B THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2016-04-21 WO disclosed
EP-0985674-B1 ORGANIC COMPOUNDS CONTAINING SILICON OR GERMANIUM, TRANSITION METAL COMPLEXES, CATALYST FOR ALPHA-OLEFIN POLYMERIZATION, AND PROCESSES FOR PRODUCING ALPHA-OLEFIN POLYMERS MITSUBISHI CHEM CORP (JP) 2003-04-23 EP disclosed
US-6255515-B1 COORDINATION POLYMERIZATION CATALYSTS MITSUBISHI CHEMICAL CORPORATION (JP) 2001-07-03 US disclosed
EP-0985674-A1 ORGANIC COMPOUNDS CONTAINING SILICON OR GERMANIUM, TRANSITION METAL COMPLEXES, CATALYST FOR $g(a)-OLEFIN POLYMERIZATION, AND PROCESSES FOR PRODUCING $g(a)-OLEFIN POLYMERS MITSUBISHI CHEMICAL CORPORATION (JP) 2000-03-15 EP disclosed